Top

28-07-2017 | PARP inhibitors | Article

PARP Inhibitors in Breast Cancer: Latest Evidence

Journal: Current Breast Cancer Reports

Authors: Ryan M. Ponec, Parvin Peddi, Rena D. Callahan

Abstract

Purpose of Review

Breast cancer treatment continues to evolve as targeted therapeutic strategies are developed for the various molecular subtypes of breast cancer. The PARP inhibitors represent a novel targeted therapy for tumors with defective homologous recombination DNA repair. These agents may become standard new treatment options for patients harboring BRCA1/2 mutations and show promise in BRCA1/2 wild-type patients with triple-negative breast cancers, which are treated predominantly with traditional cytotoxic chemotherapy. This review will discuss the results of clinical trials of these agents in breast cancer as well as important ongoing and anticipated trials.

Recent Findings

Recent reports support the use of olaparib monotherapy in BRCA1/2-mutated metastatic cancer. Results of PARP inhibitor combinations with chemotherapy have been mixed. The addition of veliparib failed to improve pathological complete response rates in patients with early-stage triple-negative breast cancer treated with carboplatin (AUC6) and paclitaxel followed by doxorubicin plus cyclophosphamide in a phase 3 trial. The PARP inhibitors talazoparib and olaparib are currently being tested in the neoadjuvant and adjuvant settings but impact on survival measures will likely take years prior to reporting in these early-stage breast cancer studies.

Summary

While data from the first phase 3 trials of PARP inhibitors in breast cancers are encouraging in patients with germline deleterious BRCA1/2 mutations, continued work is needed to elucidate their utility beyond the BRCA1/2-mutated population as has been possible in ovarian cancer. Additionally, defining the ideal population and setting for combination treatment remains a challenge and has been limited by synergistic toxicities.

Masoud V, Pages G. Targeted therapies in breast cancer: new challenges to fight against resistance. World J Clin Oncol. 2017;8(2):120–34. doi:10.5306/wjco.v8.i2.120.CrossRefPubMedPubMedCentral

Liu FW, Tewari KS. New targeted agents in gynecologic cancers: synthetic lethality, homologous recombination deficiency, and PARP inhibitors. Curr Treat Options in Oncol. 2016;17(3):12. doi:10.1007/s11864-015-0378-9.CrossRef

Lee J, Ledermann JA, Kohn EC. PARP inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol. 2014;25(1):32–40. doi:10.1093/annonc/mdt384.CrossRefPubMed

Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. BioEssays. 2004;26(8):882–93. doi:10.1002/bies.20085.CrossRefPubMed

Dziadkowiec KN, Gasiorowska E, Nowak-Markwitz E, Jankowska A. PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting. Prz Menopauzalny. 2016;15(4):215–9. doi:10.5114/pm.2016.65667.PubMed

Morales JC, Li L, Fattah FJ, Dong Y, Bey EA, Patel M, et al. Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases. Crit Rev Eukaryot Gene Expr. 2014;24(1):15–28.CrossRefPubMedPubMedCentral

Dréan A, Lord CJ, Ashworth A. PARP inhibitor combination therapy. Crit Rev Oncol Hematol. 108:73–85. doi:10.1016/j.critrevonc.2016.10.010.

Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376(9737):235–44. doi:10.1016/S0140-6736(10)60892-6.CrossRefPubMed

Liu X, Shi Y, Magg DX, Palma JP, Patterson MJ, Ellis PA, et al. Iniparib non-selectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res. 2011; doi:10.1158/1078-0432.ccr-11-1973.

10.

O'Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M, et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol. 2014;32(34):3840–7. doi:10.1200/jco.2014.55.2984.CrossRefPubMed

11.

Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res. 2013;19(18):5003–15. doi:10.1158/1078-0432.ccr-13-1391.CrossRefPubMed

12.

Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmana J, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33(3):244–50. doi:10.1200/jco.2014.56.2728.CrossRefPubMed

13.

Robson M, Im S-A, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a Germline BRCA mutation. N Engl J Med. 2017; doi:10.1056/NEJMoa1706450.

14.

Dent RA, Lindeman GJ, Clemons M, Wildiers H, Chan A, McCarthy NJ, et al. Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. Breast Cancer Res. 2013;15(5):R88. doi:10.1186/bcr3484.CrossRefPubMedPubMedCentral

15.

Balmaña J, Tung NM, Isakoff SJ, Graña B, Ryan PD, Saura C, et al. Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors. Ann Oncol. 2014;25(8):1656–63. doi:10.1093/annonc/mdu187.CrossRefPubMed

16.

Domchek S, Bang Y, Coukos G, Kobayashi K, Baker N, McMurtry E, et al. MEDIOLA: a phase I/II, open-label trial of olaparib in combination with durvalumab (MEDI4736) in patients (pts) with advanced solid tumours. Ann Oncol. 2016;27(6):359–78. doi:10.1093/annonc/mdw378.

17.

Tutt ANJ, Kaufman B, Gelber RD, Mc Fadden E, Goessl CD, Viale G, et al. OlympiA: a randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm). J Clin Oncol. 2015;33(15_suppl):TPS1109–TPS. doi:10.1200/jco.2015.33.15_suppl.tps1109.

18.

de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, et al. Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced Germline BRCA1/2 mutations and selected sporadic cancers. Cancer Discov. 2017;7(6):620–9. doi:10.1158/2159-8290.cd-16-1250.CrossRefPubMed

19.

Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke E-M, et al. Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO). J Clin Oncol. 2017;35(15_suppl):1007. doi:10.1200/JCO.2017.35.15_suppl.1007.

20.

Roche H, Blum J, Eiermann W, Im YH, Martin M, Mina L, et al. P1.01A phase 3 study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with advanced breast cancer (EMBRACA). Ann Oncol. 2015;26(suppl_2):ii16–ii. doi:10.1093/annonc/mdv090.1.CrossRef

21.

Afghahi A, Chang PJ, Ford J, Telli M. Abstract OT2-05-04: The Talazoparib Beyond BRCA (TBB) trial: A phase II clinical trial of talazoparib (BMN 673) in BRCA1 and BRCA2 wild-type patients with (i) advanced triple-negative breast cancer (TNBC) and homologous recombination deficiency (HRD) as assessed by myriad genetics HRD assay, and (ii) advanced HER2-negative breast cancer (BC) with either a germline or somatic mutation in homologous recombination (HR) pathway genes. Cancer Res. 2016;76(4 Supplement):OT2–05-4-OT2--4. doi:10.1158/1538–7445.sabcs15-ot2-05-04.

22.

Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Kelley RK, Melisko ME, et al. A phase I study of carboplatin and talazoparib in patients with and without DNA repair mutations. J Clin Oncol. 2017;35(15_suppl):2527. doi:10.1200/JCO.2017.35.15_suppl.2527.

23.

Litton JK, Scoggins M, Whitman GJ, Barcenas CH, Moulder SL, Murthy RK, et al. A feasibility study of neoadjuvant talazoparib for early-stage breast cancer patients with a germline BRCA pathogenic variant: NCT02282345. J Clin Oncol. 2017;35(15_suppl):TPS595–TPS. doi:10.1200/JCO.2017.35.15_suppl.TPS595.

24.

Litton JK, Scoggins M, Ramirez DL, Murthy RK, Whitman GJ, Hess KR, et al. A pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation. Ann Oncol. 2016;27(suppl_6):153PD. doi:10.1093/annonc/mdw364.10.CrossRef

25.

Syed YY. Rucaparib: first global approval. Drugs. 2017:1–8. doi:10.1007/s40265-017-0716-2.

26.

Kristeleit RS, Burris HA, LoRusso P, Patel MR, Asghar US, El-Khouly F, et al. Phase 1/2 study of oral rucaparib: final phase 1 results. J Clin Oncol. 2014;32(15_suppl):2573. doi:10.1200/jco.2014.32.15_suppl.2573.

27.

Drew Y, Ledermann J, Hall G, Rea D, Glasspool R, Highley M, et al. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. Br J Cancer. 2016;114(7):723–30. doi:10.1038/bjc.2016.41.CrossRefPubMedPubMedCentral

28.

Patsouris A, Vicier C, Campion L, Gouraud W, Jimenez M, Pezzella V, et al. An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity: RUBY. J Clin Oncol. 2017;35(15_suppl):TPS1117–TPS. doi:10.1200/JCO.2017.35.15_suppl.TPS1117.

29.

Wilson RH, Evans TRJ, Middleton MR, Molife LR, Spicer J, Dieras V, et al. A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. Br J Cancer. 2017;116(7):884–92. doi:10.1038/bjc.2017.36.CrossRefPubMedPubMedCentral

30.

Miller K, Tong Y, Jones DR, Walsh T, Danso MA, Ma CX et al. Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer: Final efficacy results of Hoosier Oncology Group BRE09-146. Am Soc Clin Oncol. 2015.

31.

Toms C, Chopra N, Houlton L, Jarman K, Kilburn L, Bliss J et al. Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO). Ann Oncol. 2016;27(suppl_6):219TiP-TiP. doi:10.1093/annonc/mdw364.75.

32.

Wagner LM. Profile of veliparib and its potential in the treatment of solid tumors. Onco Targets Ther. 2015;8:1931–9. doi:10.2147/OTT.S69935.CrossRefPubMedPubMedCentral

33.

Pahuja S, Beumer JH, Appleman LJ, Tawbi HA-H, Stoller RG, Lee JJ, et al. Outcome of BRCA 1/2-mutated (BRCA+) and triple-negative, BRCA wild type (BRCA-wt) breast cancer patients in a phase I study of single-agent veliparib (V). J Clin Oncol. 2014;32(26_suppl):135. doi:10.1200/jco.2014.32.26_suppl.135.CrossRef

34.

Somlo G, Frankel PH, Arun BK, Ma CX, Garcia AA, Cigler T, et al. Efficacy of the PARP inhibitor veliparib with carboplatin or as a single agent in patients with Germline brca1- or brca2-associated metastatic breast cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res. 2017; doi:10.1158/1078–0432.ccr-16-2714.

35.

Pahuja S, Beumer JH, Appleman LJ, Tawbi HA-H, Stoller RG, Lee JJ, et al. A phase I study of veliparib (ABT-888) in combination with weekly carboplatin and paclitaxel in advanced solid malignancies and enriched for triple-negative breast cancer (TNBC). J Clin Oncol. 2015;33(15_suppl):1015. doi:10.1200/jco.2015.33.15_suppl.1015.

36.

Wesolowski R, Zhao M, Geyer SM, Lustberg MB, Mrozek E, Layman RM et al. Phase I trial of the PARP inhibitor veliparib (V) in combination with carboplatin (C) in metastatic breast cancer (MBC). Am Soc Clin Oncol. 2014.

37.

Han H, Diéras V, Robson M, Palácová M, Marcom P, Jager A et al. Abstract S2-05: efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: A randomized, phase 2 study. Cancer Res. 2017;77(4 Supplement):S2–05-S2-. doi:10.1158/1538–7445.sabcs16-s2-05.

38.

Puhalla S, Han HS, Diéras V, Friedlander M, Somlo G, Arun B, et al. Phase 3 randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2-BRCA-associated locally advanced or metastatic breast cancer (BC). J Clin Oncol. 2015;33(15_suppl):TPS1102–TPS. doi:10.1200/jco.2015.33.15_suppl.tps1102.

39.

Rodler ET, Kurland BF, Griffin M, Gralow JR, Porter P, Yeh RF, et al. Phase I study of Veliparib (ABT-888) combined with Cisplatin and Vinorelbine in advanced triple-negative breast cancer and/or BRCA mutation-associated breast cancer. Clin Cancer Res. 2016;22(12):2855–64. doi:10.1158/1078-0432.ccr-15-2137.CrossRefPubMedPubMedCentral

40.

Rugo HS, Olopade OI, DeMichele A, Yau C, van ‘t Veer LJ, Buxton MB, et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. N Engl J Med. 2016;375(1):23–34. doi:10.1056/NEJMoa1513749.CrossRefPubMedPubMedCentral

41.

Geyer CE, O'Shaughnessy J, Untch M, Sikov W, Rugo HS, McKee MD, et al. Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC). J Clin Oncol. 2017;35(15_suppl):520. doi:10.1200/JCO.2017.35.15_suppl.520.

42.

FDA approves maintenance treatment for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancers. 2017. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm548948.htm. Accessed 29 Jun 2017.

43.

Murai J, Huang S-YN, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72(21):5588–99. doi:10.1158/0008-5472.can-12-2753.CrossRefPubMedPubMedCentral

44.

Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013;14(9):882–92. doi:10.1016/S1470-2045(13)70240-7.CrossRefPubMed

45.

Tryfonidis K, Bogaerts J, Martell RE, Sledge GW, Balmaña J, Audeh MW, et al. A phase III randomized trial of niraparib versus physician’s choice in previously treated, HER2-negative, germline-BRCA mutated breast cancer patients: intergroup study EORTC-1307-BCG and BIG5-13. J Clin Oncol. 2014;32(15_suppl):TPS659–TPS. doi:10.1200/jco.2014.32.15_suppl.tps659.

46.

TESARO Announces expanded development program for niraparib focused on the treatment of front-line metastatic ovarian and lung cancers and metastatic breast cancer. 2017. http://ir.tesarobio.com/releasedetail.cfm?releaseid=1018917. Accessed 29 Jun 2017.

47.

Konstantinopoulos P, Moore KN, Sachdev JC, Mita MM, Vinayak S, Seward SM, et al. Phase I/II study of niraparib plus pembrolizumab in patients with triple-negative breast cancer or recurrent ovarian cancer (KEYNOTE-162). J Clin Oncol. 2016;34(15_suppl):TPS5599–TPS. doi:10.1200/JCO.2016.34.15_suppl.TPS5599.

48.

Plummer R, Stephens P, Aissat-Daudigny L, Cambois A, Moachon G, Brown PD, et al. Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors. Cancer Chemother Pharmacol. 2014;74(2):257–65. doi:10.1007/s00280-014-2486-9.CrossRefPubMedPubMedCentral

49.

Szekely B, Silber AL, Pusztai L. New therapeutic strategies for triple-negative breast cancer oncology. (Williston Park, NY). 2017;31(2).

Medicine Matters Oncology

Abstract

Purpose of Review

Recent Findings

Summary